Specialty code 183500000X · San Jose, CA
NPI
1336559723
Since 2014
Specialty
Specialty code 183500000X
Code 183500000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
250 Hospital Pkwy
San Jose, CA, 95119
Phone (408) 363-4569
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$263K
2,447 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Evelyn M Damate-Senga prescribed most often to Medicare patients was Atorvastatin Calcium, with 347 prescriptions and refills. In total Evelyn M Damate-Senga wrote 2,447 Medicare prescriptions that cost $263K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-05-06.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Atorvastatin Calcium Generic | 347 | 1,154 | 144 | $4,242 |
| Metformin Hcl Er Metformin Hcl | 293 | 951 | 127 | $2,941 |
| Glipizide Generic | 221 | 726 | 94 | $3,201 |
| Metformin Hcl Generic | 133 | 435 | 54 | $1,671 |
| Jardiance Empagliflozin | 130 | 424 | 57 | $87K |
| Losartan Potassium Generic | 114 | 375 | 48 | $1,551 |
| Insulin Glargine-Yfgn Generic | 103 | 282 | 52 | $13K |
| Humulin N Insulin Nph Human Isophane | 101 | 300 | 50 | $17K |
| Veo Insulin Syringe Syringe-Needle,insulin,0.5 Ml | 91 | 291 | 46 | $2,411 |
| Humulin R Insulin Regular, Human | 87 | 238 | 33 | $14K |
| Lisinopril Generic | 87 | 290 | 42 | $1,099 |
| Ozempic Semaglutide | 85 | 87 | 20 | $63K |
| Glipizide Er Glipizide | 64 | 208 | 30 | $1,864 |
| Amlodipine Besylate Generic | 64 | 211 | 28 | $819 |
| Simvastatin Generic | 49 | 163 | 18 | $572 |
Brand drugs: 606 claims; generic drugs: 1,645 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Evelyn M Damate-Senga were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.